We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TDT

News List

beti-cel gene therapy demonstrates durable efficacy in beta thalassaemia patients europeanpharmaceuticalreview
June 18, 2021
The betibeglogene autotemcel (beti-cel) gene therapy caused paediatric and adult beta thalassaemia patients to achieve transfusion independence lasting over two years.
Bluebird bags EU conditional marketing authorisation for Zynteglo pharmatimes
June 05, 2019
Bluebird bio has announced that its gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) has been granted conditional marketing authorisation in Europe for certain patients 12 years and older with transfusion-dependent β-thalassaemi
First gene therapy recommended for approval in the EU for TDT pharmaceutical-technology
April 03, 2019
US-based therapeutics developer bluebird bio has secured positive recommendation from a European Medicines Agency (EMA) panel for the approval of its first gene therapy Zynteglo to treat certain patients with transfusion-dependent β-thalassemia (TDT).
ASH18: New data can’t lift Bluebird Bio’s depressed shares fiercebiotech
January 03, 2019
Bluebird Bio has been singing the praises of two new therapies at the annual American Society of Hematology, but although the data look solid so far, investors don’t seem to be fully on board with the program.......